Posted by Michael Wonder on 14 Apr 2020
LifeMax receives fast track designation for LM-030 for the treatment of Netherton syndrome
14 April 2020 - LifeMax Laboratories today announced that the FDA granted fast track designation to LM-030, an investigational therapy licensed from Novartis and currently in a Phase 2/3 pivotal clinical trial for the treatment of Netherton syndrome.
LM-030 previously received orphan drug designation from both the FDA and European Commission as well as rare paediatric disease designation from the FDA.
